Delivery Order SPE2DR25D2211-SPE2DR26FM2S2
- Not listed
- The Defense Logistics Agency awarded a $2,010.28 delivery order to AmerisourceBergen Drug Corp for 90 capsules of Lisdexamfetamine 60 mg, a controlled pharmaceutical product used to treat attention-deficit/hyperactivity disorder. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 20 mg, a controlled substance commonly used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, valued at $1,072.01, was competitively awarded without set-aside designation and is scheduled for completion by September 25, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $2,181.08 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 30 mg, a controlled pharmaceutical used to treat attention deficit hyperactivity disorder. This firm fixed-price delivery order, which became effective on August 5, 2025 with an ultimate completion date of August 6, 2025, was awarded without a set-aside designation through open competition. The order will be performed at AmerisourceBergen's corporate office location...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,768.95 for 90 capsules of Lisdexamfetamine 60 mg on July 14, 2025, with an ultimate completion date of July 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,070.16 for 100 capsules of Lisdexamfetamine 40 mg, a Schedule II controlled substance commonly prescribed for attention deficit hyperactivity disorder. This firm fixed-price delivery order, awarded on October 29, 2025, with an ultimate completion date of October 30, 2025, was competitively awarded with no set-aside designation. The order will be fulfilled from AmerisourceBergen's location in...
- The Defense Logistics Agency awarded a delivery order valued at $1,240.57 to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 40 mg, a Schedule II controlled substance commonly prescribed for attention-deficit/hyperactivity disorder. The contract was competitively awarded on June 25, 2025, with an ultimate completion date of June 26, 2025, and is classified as a firm fixed-price delivery order with no set-aside designation. Performance will occur at AmerisourceBergen's...
- The Defense Logistics Agency has awarded a $3,574.42 delivery order to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 10 mg, a controlled substance commonly prescribed for attention-deficit/hyperactivity disorder treatment. The contract is firm fixed price with no set-aside designation and is scheduled for completion by October 24, 2025. This delivery order represents a single transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal...
- The Defense Logistics Agency awarded a $2,949.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 40 mg, a controlled substance commonly prescribed for attention deficit hyperactivity disorder. This delivery order, issued on September 8, 2025, with completion targeted for September 9, 2025, represents a routine pharmaceutical procurement to support federal medical supply needs. The contract was competitively awarded with no set-aside designation...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 7, 2025, for the supply of Lisdexamfetamine 30 mg capsules (100 count) with a ceiling value of $1,181.21. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The order is scheduled for completion by November 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $2,051.06 firm fixed price delivery order to AmerisourceBergen Drug Corp for 100 capsules of Lisdexamfetamine 30 mg, a Schedule II controlled substance commonly used to treat attention deficit hyperactivity disorder. The order was competitively awarded without a set-aside designation and is scheduled for completion by September 16, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- SPE2DR25D2211Indefinite Delivery Contract
- SPE2DR25D2211-SPE2DR26FM2S2Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,045.17 to AmerisourceBergen Drug Corp for 90 capsules of Lisdexamfetamine 30 mg, a controlled pharmaceutical used to treat attention deficit hyperactivity disorder. The contract was competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of November 6, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications, vaccines, and medical supplies to support military healthcare programs and the Defense Health Agency worldwide. The delivery order aligns with the DLA's medical supply chain operations and supports federal healthcare system needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 11/5/25 |